Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating whether Hims & Hers violated federal securities laws by making false or misleading statements during the Class Period from April 29, 2025, to June 22, 2025 [1]. - Following the termination of a partnership with Novo Nordisk due to unauthorized marketing and sale of compounded semaglutide drugs, Hims & Hers' shares dropped over 34% on June 23, 2025 [2]. - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2]. Group 2: Legal Action - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other harmed investors [3].
Berger Montague Investigates Securities Class Action Against Hims & Hers Health Inc. (NYSE: HIMS)